L
Latigo Biotherapeutics
LTGORecent IPOLatigo Biotherapeutics, Inc. · Nasdaq · Non-opioid pain therapeutics · Report filing 2026/08/07 · SEC checked 2026-10-07
DAILY SEC UPDATE424B4 analysed from the latest filing
Latigo Biotherapeutics is offering 19.2 million shares of common stock at $18.00 per share under ticker LTGO, with estimated net proceeds of approximately $315.7 million.
One-minute decisionBASIC RESEARCHSource completeness · 84%
Newly listed — review valuation, deal quality and post-IPO supply before acting
Latigo Biotherapeutics, Inc. began trading on 2026-08-07 at an IPO price of $18.00; the final prospectus and offer terms are linked to SEC EDGAR.
Capital destination
—No estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · 424B4 ↗Capital destination
—No estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · 424B4 ↗BOOKRUNNERS / LEAD UNDERWRITERSUnderwriting syndicate
CONFIRMED- 1Goldman Sachs & Co. LLC39.00%7,488,000 shares
- 2Jefferies LLC28.00%5,376,000 shares
- 3Leerink Partners LLC21.00%4,032,000 shares
View all 4 institutions ＋
- 4Guggenheim Securities, LLC12.00%2,304,000 shares
Fully diluted valuation bridge
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Basic-price scenario
A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.
Check the source · 424B4 ↗Existing holders
~69.6%*The estimate compares offered shares with the latest reported shares outstanding and is not a voting-control conclusion.
Latest available filing · 2026/08/07
Review the beneficial-ownership table and voting rights together
One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Calendar dates from 2026-08-07
- First trading day19.200M IPO shares
| Holder / event | Term / date | Conditions |
|---|---|---|
| First trading day | 2026-08-07 ~30.4%* · 19.200M IPO shares | 19.200M IPO shares |
Basis and evidence
First trading day
First trading day · 19.200M IPO shares
Lock-up / shares eligible for future sale ↗Financial quality and runway
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Latest filing update
Loading saved filing update…
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Monitor
- First post-IPO filing and lock-up schedule
- Evidence
- 424B4 · 2026/08/07 ↗
Document424B4✓ Verified against the SEC source · SEC source document
Filed2026/08/071 public filings identified
Research updated2026/08/07SEC EDGAR
Evidence coverage84%Final prospectus, offer price, listing date and headline financial evidence reconciled
What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.
View the filing's actual first page ＋
